Frequent . . O O
alterations . . O O
in . . O O
gene . . O O
expression . . O O
in . . O O
colon . . O O
tumor . . O O
cells . . O O
of . . O O
the . . O O
microsatellite . . O O
mutator . . O O
phenotype . . O O
. . . O O

Tumors . . O O
of . . O O
the . . O O
microsatellite . . O O
mutator . . O O
phenotype . . O O
( . . O O
MMP . . O O
) . . O O
are . . O O
characterized . . O O
by . . O O
the . . O O
accumulation . . O O
of . . O O
many . . O O
thousands . . O O
of . . O O
somatic . . O O
mutations . . B-Mutation B-Mutation
in . . O O
tracts . . O O
of . . O O
simple . . O O
repeated . . O O
sequences . . O O
or . . O O
microsatellites . . O O
. . . O O

Using . . O O
arbitrarily . . O O
primed . . O O
PCR . . O O
fingerprinting . . O O
of . . O O
RNA . . O O
( . . O O
RAP . . O O
- . . O O
PCR . . O O
) . . O O
, . . O O
we . . O O
have . . O O
comparatively . . O O
analyzed . . O O
the . . O O
overall . . O O
gene . . O O
expression . . O O
patterns . . O O
of . . O O
several . . O O
colorectal . . O O
tumor . . O O
cell . . O O
lines . . O O
with . . O O
and . . O O
without . . O O
the . . O O
MMP . . O O
. . . O O

A . . O O
reproducible . . O O
pattern . . O O
of . . O O
30 . . O O
- . . O O
40 . . O O
main . . O O
products . . O O
was . . O O
obtained . . O O
for . . O O
each . . O O
fingerprint . . O O
with . . O O
a . . O O
total . . O O
of . . O O
about . . O O
200 . . O O
cell . . O O
transcripts . . O O
analyzed . . O O
. . . O O

Differences . . O O
in . . O O
RAP . . O O
- . . O O
PCR . . O O
fingerprints . . O O
were . . O O
detected . . O O
between . . O O
these . . O O
tumor . . O O
cell . . O O
lines . . O O
. . . O O

Some . . O O
of . . O O
these . . O O
expression . . O O
polymorphisms . . O O
appeared . . O O
to . . O O
be . . O O
specific . . O O
for . . O O
tumor . . O O
cells . . O O
of . . O O
the . . O O
MMP . . O O
because . . O O
they . . O O
were . . O O
present . . O O
in . . O O
two . . O O
or . . O O
more . . O O
different . . O O
MMP . . O O
+ . . O O
cell . . O O
lines . . O O
but . . O O
absent . . O O
in . . O O
all . . O O
MMP . . O O
- . . O O
cell . . O O
lines . . O O
analyzed . . O O
. . . O O

We . . O O
also . . O O
analyzed . . O O
RNAs . . O O
prepared . . O O
from . . O O
single . . O O
cell . . O O
clones . . O O
isolated . . O O
from . . O O
these . . O O
tumor . . O O
cell . . O O
lines . . O O
. . . O O

Reproducible . . O O
differences . . O O
in . . O O
the . . O O
fingerprints . . O O
were . . O O
detected . . O O
between . . O O
single . . O O
cell . . O O
clones . . O O
from . . O O
each . . O O
of . . O O
the . . O O
cell . . O O
lines . . O O
analyzed . . O O
. . . O O

Examples . . O O
of . . O O
single . . O O
cell . . O O
clone . . O O
- . . O O
specific . . O O
fingerprint . . O O
differences . . O O
from . . O O
one . . O O
of . . O O
the . . O O
MMP . . O O
tumor . . O O
cell . . O O
lines . . O O
were . . O O
cloned . . O O
and . . O O
sequenced . . O O
. . . O O

Differential . . O O
expression . . O O
of . . O O
some . . O O
of . . O O
these . . O O
sequences . . O O
was . . O O
confirmed . . O O
by . . O O
Northern . . O O
analysis . . O O
using . . O O
the . . O O
cloned . . O O
fragments . . O O
as . . O O
probes . . O O
. . . O O

Similar . . O O
fingerprint . . O O
alterations . . O O
were . . O O
also . . O O
observed . . O O
among . . O O
single . . O O
cell . . O O
clones . . O O
derived . . O O
from . . O O
single . . O O
cell . . O O
clones . . O O
from . . O O
mutator . . O O
tumor . . O O
cell . . O O
lines . . O O
, . . O O
which . . O O
appeared . . O O
to . . O O
exhibit . . O O
higher . . O O
clonal . . O O
variation . . O O
in . . O O
gene . . O O
expression . . O O
compared . . O O
with . . O O
MMP . . O O
- . . O O
cells . . O O
. . . O O

The . . O O
detection . . O O
of . . O O
inter . . O O
- . . O O
and . . O O
intra . . O O
- . . O O
tumor . . O O
alterations . . O O
in . . O O
gene . . O O
expression . . O O
by . . O O
unbiased . . O O
RAP . . O O
- . . O O
PCR . . O O
show . . O O
that . . O O
these . . O O
fluctuations . . O O
occur . . O O
with . . O O
high . . O O
frequency . . O O
in . . O O
tumor . . O O
cells . . O O
of . . O O
the . . O O
MMP . . O O
. . . O O

These . . O O
results . . O O
indicate . . O O
that . . O O
the . . O O
profound . . O O
genomic . . B-Mutation O
instability . . I-Mutation O
of . . O O
tumor . . O O
cells . . O O
of . . O O
the . . O O
MMP . . O O
is . . O O
also . . O O
reflected . . O O
in . . O O
a . . O O
high . . O O
incidence . . O O
of . . O O
alterations . . O O
in . . O O
their . . O O
patterns . . O O
of . . O O
gene . . O O
expression . . O O
. . . O O

Genomic . . O O
analysis . . O O
and . . O O
selected . . O O
molecular . . O O
pathways . . O O
in . . O O
rare . . O O
cancers . . O O
. . . O O

It . . O O
is . . O O
widely . . O O
accepted . . O O
that . . O O
many . . O O
cancers . . O O
arise . . O O
as . . O O
a . . O O
result . . O O
of . . O O
an . . O O
acquired . . O O
genomic . . B-Mutation O
instability . . I-Mutation O
and . . O O
the . . O O
subsequent . . O O
evolution . . O O
of . . O O
tumor . . O O
cells . . O O
with . . O O
variable . . O O
patterns . . O O
of . . O O
selected . . O O
and . . O O
background . . O O
aberrations . . O O
. . . O O

The . . O O
presence . . O O
and . . O O
behaviors . . O O
of . . O O
distinct . . O O
neoplastic . . O O
cell . . O O
populations . . O O
within . . O O
a . . O O
patient . . O O
' . . O O
s . . O O
tumor . . O O
may . . O O
underlie . . O O
multiple . . O O
clinical . . O O
phenotypes . . O O
in . . O O
cancers . . O O
. . . O O

A . . O O
goal . . O O
of . . O O
many . . O O
current . . O O
cancer . . O O
genome . . O O
studies . . O O
is . . O O
the . . O O
identification . . O O
of . . O O
recurring . . O O
selected . . O O
driver . . O O
events . . O O
that . . O O
can . . O O
be . . O O
advanced . . O O
for . . O O
the . . O O
development . . O O
of . . O O
personalized . . O O
therapies . . O O
. . . O O

Unfortunately . . O O
, . . O O
in . . O O
the . . O O
majority . . O O
of . . O O
rare . . O O
tumors . . O O
, . . O O
this . . O O
type . . O O
of . . O O
analysis . . O O
can . . O O
be . . O O
particularly . . O O
challenging . . O O
. . . O O

Large . . O O
series . . O O
of . . O O
specimens . . O O
for . . O O
analysis . . O O
are . . O O
simply . . O O
not . . O O
available . . O O
, . . O O
allowing . . O O
recurring . . O O
patterns . . O O
to . . O O
remain . . O O
hidden . . O O
. . . O O

In . . O O
this . . O O
paper . . O O
, . . O O
we . . O O
highlight . . O O
the . . O O
use . . O O
of . . O O
DNA . . O O
content . . O O
- . . O O
based . . O O
flow . . O O
sorting . . O O
to . . O O
identify . . O O
and . . O O
isolate . . O O
DNA . . O O
- . . O O
diploid . . O O
and . . O O
DNA . . O O
- . . O O
aneuploid . . B-Mutation O
populations . . O O
from . . O O
tumor . . O O
biopsies . . O O
as . . O O
a . . O O
strategy . . O O
to . . O O
comprehensively . . O O
study . . O O
the . . O O
genomic . . O O
composition . . O O
and . . O O
behaviors . . O O
of . . O O
individual . . O O
cancers . . O O
in . . O O
a . . O O
series . . O O
of . . O O
rare . . O O
solid . . O O
tumors . . O O
: . . O O
intrahepatic . . O O
cholangiocarcinoma . . O O
, . . O O
anal . . O O
carcinoma . . O O
, . . O O
adrenal . . O O
leiomyosarcoma . . O O
, . . O O
and . . O O
pancreatic . . O O
neuroendocrine . . O O
tumors . . O O
. . . O O

We . . O O
propose . . O O
that . . O O
the . . O O
identification . . O O
of . . O O
highly . . O O
selected . . O O
genomic . . O O
events . . O O
in . . O O
distinct . . O O
tumor . . O O
populations . . O O
within . . O O
each . . O O
tumor . . O O
can . . O O
identify . . O O
candidate . . O O
driver . . O O
events . . O O
that . . O O
can . . O O
facilitate . . O O
the . . O O
development . . O O
of . . O O
novel . . O O
, . . O O
personalized . . O O
treatment . . O O
strategies . . O O
for . . O O
patients . . O O
with . . O O
cancer . . O O
. . . O O

Correlation . . O O
of . . O O
dynamic . . O O
contrast . . O O
- . . O O
enhanced . . O O
MRI . . O O
perfusion . . O O
parameters . . O O
with . . O O
angiogenesis . . O O
and . . O O
biologic . . O O
aggressiveness . . O O
of . . O O
rectal . . O O
cancer . . O O
: . . O O
Preliminary . . O O
results . . O O
. . . O O

# . . O O
# . . O O
PURPOSE . . O O

To . . O O
investigate . . O O
whether . . O O
quantitative . . O O
parameters . . O O
derived . . O O
from . . O O
dynamic . . O O
contrast . . O O
- . . O O
enhanced . . O O
magnetic . . O O
resonance . . O O
imaging . . O O
( . . O O
DCE . . O O
- . . O O
MRI . . O O
) . . O O
are . . O O
correlated . . O O
with . . O O
angiogenesis . . O O
and . . O O
biologic . . O O
aggressiveness . . O O
of . . O O
rectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
MATERIALS . . O O
AND . . O O
METHODS . . O O

A . . O O
total . . O O
of . . O O
46 . . O O
patients . . O O
with . . O O
rectal . . O O
cancer . . O O
underwent . . O O
DCE . . O O
- . . O O
MRI . . O O
. . . O O

Using . . O O
a . . O O
two . . O O
- . . O O
compartmental . . O O
model . . O O
, . . O O
quantitative . . O O
parameters . . O O
( . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
, . . O O
kep . . O O
, . . O O
ve . . O O
, . . O O
and . . O O
iAUC . . O O
) . . O O
were . . O O
calculated . . O O
from . . O O
the . . O O
whole . . O O
- . . O O
transverse . . O O
region . . O O
of . . O O
interest . . O O
( . . O O
ROI . . O O
) . . O O
and . . O O
high . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
area . . O O
ROI . . O O
of . . O O
entire . . O O
tumors . . O O
. . . O O

Histological . . O O
specimens . . O O
were . . O O
analyzed . . O O
for . . O O
tumor . . O O
size . . O O
; . . O O
T . . O O
/ . . O O
N . . O O
stage . . O O
; . . O O
lymphatic . . O O
, . . O O
vascular . . O O
, . . O O
perineural . . O O
invasion . . O O
; . . O O
expression . . O O
of . . O O
epidermal . . O O
growth . . O O
factor . . O O
receptor . . O O
( . . O O
EGFR . . O O
) . . O O
; . . O O
and . . O O
KRAS . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Tumor . . O O
angiogenesis . . O O
was . . O O
evaluated . . O O
based . . O O
on . . O O
the . . O O
microvessel . . O O
density . . O O
( . . O O
MVD . . O O
) . . O O
and . . O O
the . . O O
expression . . O O
level . . O O
of . . O O
the . . O O
vascular . . O O
endothelial . . O O
growth . . O O
factor . . O O
. . . O O

Correlations . . O O
of . . O O
the . . O O
DCE . . O O
- . . O O
MRI . . O O
parameters . . O O
with . . O O
histological . . O O
markers . . O O
and . . O O
angiogenesis . . O O
were . . O O
determined . . O O
using . . O O
Student . . O O
' . . O O
s . . O O
t . . O O
- . . O O
test . . O O
and . . O O
analysis . . O O
of . . O O
variance . . O O
( . . O O
ANOVA . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
mean . . O O
kep . . O O
from . . O O
high . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
area . . O O
ROIs . . O O
showed . . O O
a . . O O
significantly . . O O
positive . . O O
correlation . . O O
with . . O O
MVD . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
030 . . O O
, . . O O
r . . O O
= . . O O
0 . . O O
. . . O O
514 . . O O
, . . O O
R . . O O
( . . O O
2 . . O O
) . . O O
= . . O O
0 . . O O
. . . O O
264 . . O O
) . . O O
. . . O O

The . . O O
mean . . O O
kep . . O O
from . . O O
the . . O O
whole . . O O
- . . O O
transverse . . O O
ROIs . . O O
showed . . O O
a . . O O
significant . . O O
inverse . . O O
correlation . . O O
with . . O O
T . . O O
stage . . O O
( . . O O
T1 . . O O
vs . . O O
. . . O O
T2 . . O O
- . . O O
4 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
021 . . O O
) . . O O
. . . O O

EGFR . . O O
- . . O O
positive . . O O
cancer . . O O
displayed . . O O
higher . . O O
mean . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
045 . . O O
) . . O O
and . . O O
kep . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
038 . . O O
) . . O O
than . . O O
EGFR . . O O
- . . O O
negative . . O O
cancer . . O O
in . . O O
whole . . O O
- . . O O
transverse . . O O
ROIs . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

These . . O O
preliminary . . O O
results . . O O
suggest . . O O
that . . O O
the . . O O
determination . . O O
of . . O O
kep . . O O
of . . O O
high . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
area . . O O
permits . . O O
the . . O O
noninvasive . . O O
estimation . . O O
of . . O O
tumor . . O O
angiogenesis . . O O
in . . O O
rectal . . O O
cancer . . O O
and . . O O
that . . O O
DCE . . O O
- . . O O
MRI . . O O
parameters . . O O
can . . O O
be . . O O
used . . O O
as . . O O
imaging . . O O
biomarkers . . O O
to . . O O
predict . . O O
the . . O O
biologic . . O O
aggressiveness . . O O
of . . O O
the . . O O
tumor . . O O
and . . O O
patient . . O O
prognosis . . O O
. . . O O

Microsatellite . . B-Mutation O
instability . . I-Mutation O
is . . O O
a . . O O
predictive . . O O
factor . . O O
of . . O O
the . . O O
tumor . . O O
response . . O O
to . . O O
irinotecan . . O O
in . . O O
patients . . O O
with . . O O
advanced . . O O
colorectal . . O O
cancer . . O O
. . . O O

The . . O O
aim . . O O
of . . O O
our . . O O
study . . O O
was . . O O
to . . O O
assess . . O O
the . . O O
relationship . . O O
between . . O O
colorectal . . O O
tumor . . O O
responsiveness . . O O
to . . O O
irinotecan . . O O
and . . O O
microsatellite . . B-Mutation O
instability . . I-Mutation O
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
, . . O O
a . . O O
feature . . O O
of . . O O
colorectal . . O O
tumors . . O O
with . . O O
DNA . . O O
mismatch . . O O
repair . . O O
defect . . O O
. . . O O

Seventy . . O O
- . . O O
two . . O O
patients . . O O
with . . O O
metastatic . . O O
colorectal . . O O
cancer . . O O
were . . O O
included . . O O
in . . O O
our . . O O
retrospective . . O O
study . . O O
. . . O O

A . . O O
complete . . O O
response . . O O
to . . O O
irinotecan . . O O
was . . O O
observed . . O O
in . . O O
1 . . O O
patient . . O O
and . . O O
a . . O O
partial . . O O
response . . O O
in . . O O
10 . . O O
patients . . O O
, . . O O
whereas . . O O
61 . . O O
patients . . O O
did . . O O
not . . O O
respond . . O O
to . . O O
this . . O O
treatment . . O O
. . . O O

We . . O O
analyzed . . O O
the . . O O
protein . . O O
expression . . O O
of . . O O
hMLH1 . . O O
, . . O O
hMSH2 . . O O
, . . O O
and . . O O
BAX . . O O
by . . O O
immunohistochemistry . . O O
, . . O O
determined . . O O
the . . O O
MSI . . B-Mutation B-Mutation
phenotype . . O O
, . . O O
and . . O O
looked . . O O
for . . O O
mutations . . O B-Mutation
in . . O O
the . . O O
coding . . O O
repeats . . O O
located . . O O
in . . O O
the . . O O
transforming . . O O
growth . . O O
factor . . O O
beta . . O O
- . . O O
RII . . O O
, . . O O
BAX . . O O
, . . O O
hMSH3 . . O O
, . . O O
and . . O O
hMSH6 . . O O
genes . . O O
. . . O O

All . . O O
44 . . O O
tumors . . O O
analyzed . . O O
expressed . . O O
detectable . . O O
levels . . O O
of . . O O
hMLH1 . . O O
; . . O O
1 . . O O
tumor . . O O
lacked . . O O
hMSH2 . . O O
staining . . O O
, . . O O
whereas . . O O
4 . . O O
tumors . . O O
showed . . O O
a . . O O
marked . . O O
decrease . . O O
in . . O O
BAX . . O O
expression . . O O
. . . O O

A . . O O
better . . O O
response . . O O
to . . O O
irinotecan . . O O
was . . O O
observed . . O O
in . . O O
the . . O O
patients . . O O
whose . . O O
tumors . . O O
have . . O O
lost . . O O
BAX . . O O
expression . . O O
( . . O O
P . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
. . . O O

Among . . O O
the . . O O
7 . . O O
tumors . . O O
that . . O O
displayed . . O O
a . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
phenotype . . O O
, . . O O
4 . . O O
responded . . O O
to . . O O
irinotecan . . O O
, . . O O
whereas . . O O
only . . O O
7 . . O O
of . . O O
the . . O O
65 . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
L . . I-Mutation O
/ . . O O
microsatellite . . O O
stable . . O O
tumors . . O O
did . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
009 . . O O
) . . O O
. . . O O

Seven . . O O
of . . O O
the . . O O
72 . . O O
tumors . . O O
had . . O O
inactivating . . O O
mutations . . O B-Mutation
in . . O O
the . . O O
coding . . O O
repeats . . O O
of . . O O
the . . O O
target . . O O
genes . . O O
. . . O O

Three . . O O
tumors . . O O
displayed . . O O
a . . O O
mutation . . O B-Mutation
in . . O O
the . . O O
poly . . O O
- . . O O
A10 . . O O
tract . . O O
of . . O O
the . . O O
transforming . . O O
growth . . O O
factor . . O O
beta . . O O
- . . O O
RII . . O O
gene . . O O
, . . O O
associated . . O O
with . . O O
a . . O O
1 . . O O
- . . O O
bp . . O O
deletion . . O B-Mutation
in . . O O
the . . O O
poly . . O O
- . . O O
A8 . . O O
tract . . O O
of . . O O
hMSH3 . . O O
in . . O O
one . . O O
tumor . . O O
and . . O O
with . . O O
a . . O O
1 . . O O
- . . O O
bp . . O O
deletion . . O B-Mutation
in . . O O
the . . O O
poly . . O O
- . . O O
G8 . . O O
tract . . O O
of . . O O
BAX . . O O
in . . O O
another . . O O
. . . O O

Four . . O O
tumors . . O O
displayed . . O O
mutations . . O B-Mutation
in . . O O
the . . O O
poly . . O O
- . . O O
G8 . . O O
repeat . . O O
of . . O O
BAX . . O O
, . . O O
whereas . . O O
2 . . O O
mutations . . B-Mutation B-Mutation
in . . O O
hMSH6 . . O O
and . . O O
hMSH3 . . O O
were . . O O
characterized . . O O
. . . O O

Among . . O O
the . . O O
7 . . O O
tumors . . O O
with . . O O
mutations . . O B-Mutation
in . . O O
these . . O O
target . . O O
genes . . O O
, . . O O
5 . . O O
responded . . O O
to . . O O
irinotecan . . O O
, . . O O
whereas . . O O
only . . O O
6 . . O O
of . . O O
the . . O O
other . . O O
65 . . O O
tumors . . O O
did . . O O
( . . O O
P . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
, . . O O
indicating . . O O
that . . O O
MSI . . B-Mutation B-Mutation
- . . O O
driven . . O O
inactivation . . O O
of . . O O
target . . O O
genes . . O O
modifies . . O O
tumor . . O O
chemosensitivity . . O O
. . . O O

Our . . O O
observations . . O O
allowed . . O O
us . . O O
to . . O O
define . . O O
the . . O O
first . . O O
useful . . O O
predictive . . O O
criteria . . O O
for . . O O
irinotecan . . O O
response . . O O
in . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
. . . O O

Polymorphism . . B-Mutation O
in . . O O
the . . O O
thymidylate . . O O
synthase . . O O
promoter . . O O
enhancer . . O O
region . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenomas . . O O
. . . O O

Thymidylate . . O O
synthase . . O O
( . . O O
TS . . O O
) . . O O
, . . O O
a . . O O
key . . O O
one . . O O
- . . O O
carbon . . O O
metabolizing . . O O
gene . . O O
, . . O O
encodes . . O O
an . . O O
enzyme . . O O
that . . O O
converts . . O O
dUMP . . O O
to . . O O
dTMP . . O O
, . . O O
the . . O O
rate . . O O
- . . O O
limiting . . O O
nucleotide . . O O
in . . O O
DNA . . O O
synthesis . . O O
. . . O O

We . . O O
recently . . O O
reported . . O O
that . . O O
a . . O O
promoter . . O O
polymorphism . . B-Mutation O
in . . O O
TS . . O O
modified . . O O
the . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
as . . O O
well . . O O
as . . O O
the . . O O
survival . . O O
rate . . O O
after . . O O
the . . O O
disease . . O O
. . . O O

To . . O O
explore . . O O
whether . . O O
TS . . O O
may . . O O
play . . O O
an . . O O
important . . O O
role . . O O
in . . O O
colorectal . . O O
carcinogenesis . . O O
early . . O O
in . . O O
the . . O O
multistaged . . O O
pathogenic . . O O
pathway . . O O
, . . O O
we . . O O
investigated . . O O
the . . O O
relation . . O O
between . . O O
the . . O O
TS . . O O
promoter . . O O
polymorphism . . B-Mutation O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
in . . O O
a . . O O
nested . . O O
case . . O O
- . . O O
control . . O O
study . . O O
within . . O O
the . . O O
prospective . . O O
Health . . O O
Professionals . . O O
Follow . . O O
- . . O O
up . . O O
Study . . O O
. . . O O

We . . O O
ascertained . . O O
the . . O O
TS . . O O
genotype . . O O
from . . O O
373 . . O O
incident . . O O
colorectal . . O O
adenoma . . O O
cases . . O O
and . . O O
720 . . O O
control . . O O
subjects . . O O
. . . O O

Although . . O O
there . . O O
was . . O O
no . . O O
overall . . O O
association . . O O
between . . O O
the . . O O
TS . . O O
promoter . . O O
polymorphism . . B-Mutation O
and . . O O
adenoma . . O O
risk . . O O
, . . O O
we . . O O
observed . . O O
a . . O O
significant . . O O
TS . . O O
- . . O O
alcohol . . O O
interaction . . O O
( . . O O
P . . O O
for . . O O
interaction . . O O
= . . O O
0 . . O O
. . . O O
009 . . O O
) . . O O
; . . O O
relative . . O O
to . . O O
low . . O O
alcohol . . O O
consumers . . O O
with . . O O
the . . O O
2R . . O O
/ . . O O
2R . . O O
genotype . . O O
, . . O O
those . . O O
with . . O O
high . . O O
alcohol . . O O
consumption . . O O
( . . O O
> . . O O
30 . . O O
g . . O O
/ . . O O
d . . O O
) . . O O
were . . O O
not . . O O
at . . O O
elevated . . O O
risk . . O O
if . . O O
they . . O O
had . . O O
the . . O O
2R . . O O
/ . . O O
2R . . O O
genotype . . O O
[ . . O O
relative . . O O
risk . . O O
( . . O O
RR . . O O
) . . O O
, . . O O
0 . . O O
. . . O O
80 . . O O
; . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
( . . O O
95 . . O O
% . . O O
CI . . O O
) . . O O
, . . O O
0 . . O O
. . . O O
34 . . O O
- . . O O
1 . . O O
. . . O O
90 . . O O
] . . O O
, . . O O
but . . O O
were . . O O
at . . O O
higher . . O O
risk . . O O
if . . O O
they . . O O
had . . O O
the . . O O
2R . . O O
/ . . O O
3R . . O O
genotype . . O O
( . . O O
RR . . O O
, . . O O
1 . . O O
. . . O O
70 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
0 . . O O
. . . O O
87 . . O O
- . . O O
3 . . O O
. . . O O
31 . . O O
) . . O O
, . . O O
and . . O O
at . . O O
the . . O O
highest . . O O
risk . . O O
( . . O O
RR . . O O
, . . O O
3 . . O O
. . . O O
16 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
1 . . O O
. . . O O
50 . . O O
- . . O O
6 . . O O
. . . O O
63 . . O O
) . . O O
if . . O O
they . . O O
had . . O O
the . . O O
3R . . O O
/ . . O O
3R . . O O
genotype . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
a . . O O
significant . . O O
interaction . . O O
was . . O O
observed . . O O
between . . O O
the . . O O
TS . . O O
promoter . . O O
polymorphism . . B-Mutation O
and . . O O
the . . O O
677C . . O O
> . . O O
T . . O O
polymorphism . . B-Mutation O
of . . O O
methylenetetrahydrofolate . . O O
reductase . . O O
( . . O O
MTHFR . . O O
; . . O O
P . . O O
for . . O O
interaction . . O O
= . . O O
0 . . O O
. . . O O
007 . . O O
) . . O O
. . . O O

These . . O O
findings . . O O
lend . . O O
additional . . O O
support . . O O
that . . O O
one . . O O
- . . O O
carbon . . O O
metabolism . . O O
is . . O O
an . . O O
important . . O O
process . . O O
in . . O O
pathogenesis . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

PUMA . . O O
mediates . . O O
the . . O O
apoptotic . . O O
response . . O O
to . . O O
p53 . . O O
in . . O O
colorectal . . O O
cancer . . O O
cells . . O O
. . . O O

Although . . O O
several . . O O
genes . . O O
that . . O O
might . . O O
mediate . . O O
p53 . . O O
- . . O O
induced . . O O
apoptosis . . O O
have . . O O
been . . O O
proposed . . O O
, . . O O
none . . O O
have . . O O
previously . . O O
been . . O O
shown . . O O
to . . O O
play . . O O
an . . O O
essential . . O O
role . . O O
in . . O O
this . . O O
process . . O O
through . . O O
a . . O O
rigorous . . O O
gene . . O O
disruption . . O O
approach . . O O
. . . O O

We . . O O
used . . O O
a . . O O
gene . . O O
- . . O O
targeting . . O O
approach . . O O
to . . O O
evaluate . . O O
p53 . . O O
- . . O O
mediated . . O O
death . . O O
in . . O O
human . . O O
colorectal . . O O
cancer . . O O
cells . . O O
. . . O O

Expression . . O O
of . . O O
p53 . . O O
in . . O O
these . . O O
cells . . O O
induces . . O O
growth . . O O
arrest . . O O
through . . O O
transcriptional . . O O
activation . . O O
of . . O O
the . . O O
cyclin . . O O
- . . O O
dependent . . O O
kinase . . O O
inhibitor . . O O
p21 . . O O
. . . O O

If . . O O
p21 . . O O
is . . O O
disrupted . . O O
via . . O O
gene . . O O
targeting . . O O
, . . O O
the . . O O
cells . . O O
die . . O O
through . . O O
apoptosis . . O O
. . . O O

If . . O O
the . . O O
PUMA . . O O
gene . . O O
is . . O O
also . . O O
disrupted . . O O
in . . O O
such . . O O
cells . . O O
, . . O O
apoptosis . . O O
is . . O O
prevented . . O O
. . . O O

The . . O O
effects . . O O
of . . O O
PUMA . . O O
on . . O O
apoptosis . . O O
were . . O O
observed . . O O
after . . O O
exogenous . . O O
overexpression . . O O
of . . O O
p53 . . O O
as . . O O
well . . O O
as . . O O
after . . O O
exposure . . O O
to . . O O
hypoxia . . O O
, . . O O
a . . O O
physiologic . . O O
activator . . O O
of . . O O
p53 . . O O
, . . O O
and . . O O
DNA . . O O
damage . . O O
. . . O O

The . . O O
PUMA . . O O
protein . . O O
interacts . . O O
with . . O O
Bcl . . O O
- . . O O
X . . O O
( . . O O
L . . O O
) . . O O
and . . O O
promotes . . O O
mitochondrial . . O O
translocation . . O O
and . . O O
multimerization . . O O
of . . O O
Bax . . O O
. . . O O

Accordingly . . O O
, . . O O
genetic . . O O
disruption . . O O
of . . O O
BAX . . O O
makes . . O O
cells . . O O
resistant . . O O
to . . O O
the . . O O
apoptosis . . O O
resulting . . O O
from . . O O
PUMA . . O O
expression . . O O
. . . O O

These . . O O
results . . O O
suggest . . O O
that . . O O
the . . O O
balance . . O O
between . . O O
PUMA . . O O
and . . O O
p21 . . O O
is . . O O
pivotal . . O O
in . . O O
determining . . O O
the . . O O
responses . . O O
to . . O O
p53 . . O O
activation . . O O
and . . O O
provide . . O O
a . . O O
model . . O O
for . . O O
understanding . . O O
the . . O O
basis . . O O
of . . O O
p53 . . O O
mutations . . B-Mutation B-Mutation
in . . O O
human . . O O
cancer . . O O
. . . O O

Microsatellite . . B-Mutation O
instability . . I-Mutation O
does . . O O
not . . O O
predict . . O O
the . . O O
efficacy . . O O
of . . O O
chemotherapy . . O O
in . . O O
metastatic . . O O
colorectal . . O O
cancer . . O O
. . . O O

A . . O O
systematic . . O O
review . . O O
and . . O O
meta . . O O
- . . O O
analysis . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Microsatellite . . B-Mutation O
Instability . . I-Mutation O
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
status . . O O
is . . O O
a . . O O
good . . O O
prognostic . . O O
factor . . O O
for . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
but . . O O
its . . O O
predictive . . O O
value . . O O
for . . O O
chemosensitivity . . O O
remains . . O O
controversial . . O O
. . . O O

A . . O O
previous . . O O
meta . . O O
- . . O O
analysis . . O O
( . . O O
MA . . O O
) . . O O
in . . O O
the . . O O
adjuvant . . O O
setting . . O O
showed . . O O
that . . O O
MSI . . B-Mutation B-Mutation
- . . O O
high . . O O
( . . O O
H . . O O
) . . O O
status . . O O
did . . O O
not . . O O
predict . . O O
the . . O O
efficacy . . O O
of . . O O
chemotherapy . . O O
. . . O O

The . . O O
predictive . . O O
value . . O O
of . . O O
MSI . . B-Mutation B-Mutation
status . . O O
on . . O O
the . . O O
effect . . O O
of . . O O
metastatic . . O O
chemotherapy . . O O
was . . O O
investigated . . O O
by . . O O
MA . . O O
. . . O O

# . . O O
# . . O O
PATIENTS . . O O
AND . . O O
METHODS . . O O

Studies . . O O
were . . O O
identified . . O O
by . . O O
electronic . . O O
search . . O O
through . . O O
PubMed . . O O
, . . O O
Embase . . O O
and . . O O
ASCO . . O O
proceedings . . O O
online . . O O
databases . . O O
, . . O O
using . . O O
several . . O O
key . . O O
words . . O O
( . . O O
colorectal . . O O
cancer . . O O
, . . O O
chemotherapy . . O O
, . . O O
microsatellite . . B-Mutation O
instability . . I-Mutation O
) . . O O
. . . O O

For . . O O
each . . O O
study . . O O
, . . O O
the . . O O
ratio . . O O
of . . O O
response . . O O
rate . . O O
( . . O O
RR . . O O
) . . O O
, . . O O
complete . . O O
( . . O O
CR . . O O
) . . O O
and . . O O
partial . . O O
response . . O O
( . . O O
PR . . O O
) . . O O
divided . . O O
by . . O O
stable . . O O
disease . . O O
and . . O O
progression . . O O
was . . O O
calculated . . O O
. . . O O

From . . O O
190 . . O O
articles . . O O
and . . O O
100 . . O O
abstracts . . O O
, . . O O
only . . O O
eight . . O O
independent . . O O
studies . . O O
were . . O O
selected . . O O
. . . O O

The . . O O
data . . O O
were . . O O
analysed . . O O
with . . O O
a . . O O
random . . O O
- . . O O
effect . . O O
model . . O O
( . . O O
due . . O O
to . . O O
heterogeneity . . O O
between . . O O
studies . . O O
) . . O O
using . . O O
EasyMA . . O O
software . . O O
. . . O O

Statistical . . O O
calculations . . O O
were . . O O
performed . . O O
on . . O O
six . . O O
studies . . O O
representing . . O O
964 . . O O
patients . . O O
( . . O O
mean . . O O
age . . O O
63 . . O O
years . . O O
; . . O O
91 . . O O
MSI . . O B-Mutation
- . . O O
H . . O O
; . . O O
873 . . O O
microsatellite . . O O
stable . . O O
( . . O O
MSS . . O O
) . . O O
tumours . . O O
) . . O O
. . . O O

A . . O O
total . . O O
of . . O O
287 . . O O
patients . . O O
received . . O O
5 . . O O
- . . O O
fluorouracil . . O O
( . . O O
5FU . . O O
) . . O O
- . . O O
based . . O O
chemotherapy . . O O
, . . O O
whereas . . O O
678 . . O O
patients . . O O
received . . O O
combinations . . O O
of . . O O
5FU . . O O
or . . O O
capecitabine . . O O
with . . O O
oxaliplatin . . O O
and . . O O
/ . . O O
or . . O O
irinotecan . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

No . . O O
benefit . . O O
of . . O O
metastatic . . O O
chemotherapy . . O O
in . . O O
terms . . O O
of . . O O
RR . . O O
for . . O O
MSI . . B-Mutation B-Mutation
- . . O O
H . . O O
patients . . O O
compared . . O O
with . . O O
MSS . . O O
patients . . O O
was . . O O
found . . O O
. . . O O

The . . O O
global . . O O
hazard . . O O
ratio . . O O
( . . O O
HR . . O O
) . . O O
for . . O O
RR . . O O
was . . O O
0 . . O O
. . . O O
82 . . O O
( . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
, . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
95 . . O O
; . . O O
0 . . O O
. . . O O
65 . . O O
- . . O O
1 . . O O
. . . O O
03 . . O O
; . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
09 . . O O
) . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

MSI . . B-Mutation B-Mutation
status . . O O
does . . O O
not . . O O
predict . . O O
the . . O O
effect . . O O
of . . O O
chemotherapy . . O O
which . . O O
is . . O O
similar . . O O
in . . O O
MSI . . B-Mutation B-Mutation
- . . O O
H . . O O
and . . O O
MSS . . O O
metastatic . . O O
CRC . . O O
tumours . . O O
. . . O O

The . . O O
relationship . . O O
of . . O O
DNA . . O O
aneuploidy . . B-Mutation O
to . . O O
molecular . . O O
genetic . . O O
alterations . . O O
in . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

Altered . . O O
total . . O O
nuclear . . O O
DNA . . O O
content . . O O
is . . O O
frequent . . O O
in . . O O
colorectal . . O O
carcinomas . . O O
, . . O O
but . . O O
the . . O O
mechanisms . . O O
producing . . O O
aneuploidy . . B-Mutation O
are . . O O
unknown . . O O
. . . O O

Therefore . . O O
, . . O O
DNA . . O O
ploidy . . O O
by . . O O
flow . . O O
cytometry . . O O
was . . O O
correlated . . O O
with . . O O
molecular . . O O
genetic . . B-Mutation O
alterations . . I-Mutation O
and . . O O
tumor . . O O
characteristics . . O O
in . . O O
50 . . O O
colorectal . . O O
carcinomas . . O O
. . . O O

The . . O O
prognostic . . O O
value . . O O
of . . O O
these . . O O
alterations . . O O
was . . O O
also . . O O
evaluated . . O O
because . . O O
aneuploidy . . B-Mutation O
has . . O O
been . . O O
associated . . O O
with . . O O
poor . . O O
prognosis . . O O
. . . O O

Thirty . . O O
- . . O O
nine . . O O
of . . O O
the . . O O
carcinomas . . O O
( . . O O
78 . . O O
% . . O O
) . . O O
were . . O O
DNA . . O O
aneuploid . . B-Mutation O
. . . O O

When . . O O
compared . . O O
with . . O O
diploid . . O O
carcinomas . . O O
, . . O O
aneuploid . . B-Mutation O
tumors . . O O
had . . O O
greater . . O O
mean . . O O
fractional . . O O
allelic . . O O
loss . . O O
, . . O O
defined . . O O
as . . O O
the . . O O
fraction . . O O
of . . O O
evaluable . . O O
nonacrocentric . . O O
autosomal . . O O
arms . . O O
with . . O O
deletion . . O B-Mutation
( . . O O
0 . . O O
. . . O O
25 . . O O
+ . . O O
/ . . O O
- . . O O
0 . . O O
. . . O O
15 . . O O
, . . O O
range . . O O
0 . . O O
- . . O O
0 . . O O
. . . O O
667 . . O O
, . . O O
vs . . O O
. . . O O
0 . . O O
. . . O O
12 . . O O
+ . . O O
/ . . O O
- . . O O
0 . . O O
. . . O O
10 . . O O
, . . O O
range . . O O
0 . . O O
- . . O O
0 . . O O
. . . O O
345 . . O O
; . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
006 . . O O
) . . O O
. . . O O

DNA . . O O
index . . O O
by . . O O
flow . . O O
cytometry . . O O
correlated . . O O
with . . O O
fractional . . O O
allelic . . O O
loss . . O O
( . . O O
r . . O O
= . . O O
0 . . O O
. . . O O
38 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
006 . . O O
) . . O O
. . . O O

Aneuploid . . B-Mutation O
tumors . . O O
also . . O O
had . . O O
more . . O O
frequent . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
on . . O O
chromosome . . O O
17p . . O O
( . . O O
87 . . O O
% . . O O
vs . . O O
. . . O O
55 . . O O
% . . O O
; . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
017 . . O O
) . . O O
, . . O O
but . . O O
less . . O O
frequent . . O O
ras . . O O
gene . . O O
mutation . . O B-Mutation
( . . O O
44 . . O O
% . . O O
vs . . O O
. . . O O
82 . . O O
% . . O O
; . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
025 . . O O
) . . O O
. . . O O

Among . . O O
the . . O O
25 . . O O
right . . O O
- . . O O
sided . . O O
and . . O O
25 . . O O
left . . O O
- . . O O
sided . . O O
tumors . . O O
, . . O O
DNA . . O O
diploid . . O O
tumors . . O O
were . . O O
more . . O O
frequent . . O O
on . . O O
the . . O O
right . . O O
side . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
002 . . O O
) . . O O
, . . O O
whereas . . O O
deletion . . B-Mutation B-Mutation
of . . O O
17p . . O O
was . . O O
found . . O O
predominantly . . O O
on . . O O
the . . O O
left . . O O
side . . O O
. . . O O

Aneuploidy . . O O
was . . O O
associated . . O O
with . . O O
moderate . . O O
and . . O O
poor . . O O
differentiation . . O O
of . . O O
the . . O O
carcinomas . . O O
but . . O O
not . . O O
with . . O O
distant . . O O
metastasis . . O O
. . . O O

By . . O O
contrast . . O O
, . . O O
high . . O O
fractional . . O O
allelic . . B-Mutation O
loss . . I-Mutation O
, . . O O
deletion . . B-Mutation B-Mutation
of . . O O
17p . . O O
, . . O O
and . . O O
deletion . . B-Mutation B-Mutation
of . . O O
18q . . O O
were . . O O
associated . . O O
with . . O O
distant . . O O
metastasis . . O O
. . . O O

In . . O O
survival . . O O
analysis . . O O
of . . O O
patients . . O O
with . . O O
Dukes . . O O
' . . O O
B . . O O
or . . O O
C . . O O
carcinoma . . O O
, . . O O
DNA . . O O
aneuploidy . . B-Mutation O
was . . O O
not . . O O
a . . O O
significant . . O O
discriminator . . O O
, . . O O
but . . O O
patients . . O O
whose . . O O
tumor . . O O
had . . O O
deletion . . B-Mutation B-Mutation
of . . O O
17p . . O O
or . . O O
deletion . . B-Mutation B-Mutation
of . . O O
both . . O O
17p . . O O
and . . O O
18q . . O O
had . . O O
poorer . . O O
survival . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
045 . . O O
and . . O O
0 . . O O
. . . O O
022 . . O O
, . . O O
respectively . . O O
) . . O O
. . . O O

The . . O O
results . . O O
suggest . . O O
that . . O O
DNA . . O O
aneuploidy . . B-Mutation O
is . . O O
associated . . O O
with . . O O
some . . O O
of . . O O
the . . O O
molecular . . O O
genetic . . B-Mutation O
alterations . . I-Mutation O
and . . O O
phenotypic . . O O
characteristics . . O O
of . . O O
colorectal . . O O
carcinomas . . O O
but . . O O
is . . O O
not . . O O
a . . O O
reliable . . O O
indicator . . O O
of . . O O
metastatic . . O O
potential . . O O
. . . O O

Value . . O O
of . . O O
predictive . . O O
genetic . . O O
testing . . O O
in . . O O
management . . O O
of . . O O
hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
cancer . . O O
( . . O O
HNPCC . . O O
) . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

To . . O O
investigate . . O O
the . . O O
impact . . O O
of . . O O
predictive . . O O
genetic . . O O
testing . . O O
on . . O O
colonoscopic . . O O
surveillance . . O O
in . . O O
an . . O O
extended . . O O
family . . O O
with . . O O
hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
cancer . . O O
( . . O O
HNPCC . . O O
) . . O O
. . . O O

# . . O O
# . . O O
SETTING . . O O

Familial . . O O
Bowel . . O O
Cancer . . O O
Service . . O O
, . . O O
The . . O O
Royal . . O O
Melbourne . . O O
Hospital . . O O
, . . O O
Victoria . . O O
. . . O O

# . . O O
# . . O O
SUBJECTS . . O O

96 . . O O
people . . O O
registered . . O O
with . . O O
the . . O O
Service . . O O
who . . O O
were . . O O
apparently . . O O
unaffected . . O O
members . . O O
of . . O O
an . . O O
extended . . O O
family . . O O
that . . O O
met . . O O
the . . O O
classic . . O O
Amsterdam . . O O
criteria . . O O
for . . O O
HNPCC . . O O
and . . O O
carried . . O O
an . . O O
MLH1 . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
( . . O O
IVS9 . . B-Mutation O
+ . . I-Mutation O
3insT . . I-Mutation O
) . . O O
. . . O O

# . . O O
# . . O O
INTERVENTION . . O O

Predictive . . O O
genetic . . O O
testing . . O O
was . . O O
offered . . O O
in . . O O
a . . O O
cascade . . O O
manner . . O O
to . . O O
at . . O O
- . . O O
risk . . O O
family . . O O
members . . O O
; . . O O
mutation . . O B-Mutation
- . . O O
positive . . O O
individuals . . O O
were . . O O
advised . . O O
to . . O O
have . . O O
annual . . O O
colonoscopic . . O O
surveillance . . O O
, . . O O
while . . O O
mutation . . B-Mutation B-Mutation
- . . O O
negative . . O O
individuals . . O O
were . . O O
withdrawn . . O O
from . . O O
surveillance . . O O
. . . O O

# . . O O
# . . O O
MAIN . . O O
OUTCOME . . O O
MEASURES . . O O

Previous . . O O
compliance . . O O
with . . O O
recommended . . O O
colonoscopic . . O O
surveillance . . O O
; . . O O
uptake . . O O
and . . O O
results . . O O
of . . O O
genetic . . O O
testing . . O O
; . . O O
expected . . O O
effect . . O O
of . . O O
genetic . . O O
test . . O O
results . . O O
on . . O O
number . . O O
of . . O O
colonoscopies . . O O
over . . O O
five . . O O
years . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

22 . . O O
of . . O O
the . . O O
96 . . O O
family . . O O
members . . O O
( . . O O
23 . . O O
% . . O O
) . . O O
were . . O O
not . . O O
complying . . O O
with . . O O
recommended . . O O
surveillance . . O O
. . . O O

Of . . O O
48 . . O O
individuals . . O O
offered . . O O
predictive . . O O
genetic . . O O
testing . . O O
, . . O O
41 . . O O
( . . O O
85 . . O O
% . . O O
) . . O O
responded . . O O
and . . O O
39 . . O O
( . . O O
81 . . O O
% . . O O
) . . O O
underwent . . O O
testing . . O O
. . . O O

Seven . . O O
of . . O O
the . . O O
39 . . O O
( . . O O
18 . . O O
% . . O O
) . . O O
were . . O O
positive . . O O
for . . O O
the . . O O
family . . O O
- . . O O
specific . . O O
mutation . . B-Mutation B-Mutation
, . . O O
and . . O O
32 . . O O
( . . O O
82 . . O O
% . . O O
) . . O O
were . . O O
negative . . O O
. . . O O

The . . O O
39 . . O O
tested . . O O
individuals . . O O
and . . O O
37 . . O O
of . . O O
their . . O O
descendants . . O O
who . . O O
were . . O O
registered . . O O
with . . O O
the . . O O
screening . . O O
program . . O O
had . . O O
undergone . . O O
70 . . O O
colonoscopies . . O O
in . . O O
the . . O O
five . . O O
years . . O O
before . . O O
genetic . . O O
testing . . O O
. . . O O

In . . O O
the . . O O
five . . O O
years . . O O
after . . O O
testing . . O O
, . . O O
only . . O O
37 . . O O
surveillance . . O O
colonoscopies . . O O
were . . O O
planned . . O O
( . . O O
annual . . O O
or . . O O
two . . O O
- . . O O
yearly . . O O
colonoscopies . . O O
for . . O O
the . . O O
six . . O O
mutation . . B-Mutation B-Mutation
- . . O O
positive . . O O
individuals . . O O
and . . O O
five . . O O
- . . O O
yearly . . O O
colonoscopies . . O O
for . . O O
four . . O O
mutation . . B-Mutation B-Mutation
- . . O O
negative . . O O
individuals . . O O
with . . O O
previously . . O O
identified . . O O
adenoma . . O O
) . . O O
, . . O O
an . . O O
almost . . O O
50 . . O O
% . . O O
reduction . . O O
in . . O O
colonoscopies . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Predictive . . O O
genetic . . O O
testing . . O O
in . . O O
HNPCC . . O O
families . . O O
allows . . O O
many . . O O
individuals . . O O
to . . O O
be . . O O
withdrawn . . O O
from . . O O
regular . . O O
colonoscopic . . O O
surveillance . . O O
. . . O O

It . . O O
may . . O O
therefore . . O O
reduce . . O O
costs . . O O
, . . O O
as . . O O
well . . O O
as . . O O
have . . O O
emotional . . O O
benefits . . O O
for . . O O
many . . O O
individuals . . O O
. . . O O

Noninvasive . . O O
testing . . O O
for . . O O
colorectal . . O O
cancer . . O O
: . . O O
a . . O O
review . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVES . . O O

Colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
is . . O O
the . . O O
second . . O O
leading . . O O
cause . . O O
of . . O O
cancer . . O O
- . . O O
related . . O O
death . . O O
in . . O O
the . . O O
United . . O O
States . . O O
. . . O O

Endoscopic . . O O
screening . . O O
is . . O O
now . . O O
in . . O O
favor . . O O
and . . O O
its . . O O
use . . O O
is . . O O
increasing . . O O
, . . O O
but . . O O
overall . . O O
participation . . O O
rates . . O O
are . . O O
poor . . O O
. . . O O

A . . O O
substantial . . O O
percentage . . O O
of . . O O
the . . O O
population . . O O
will . . O O
likely . . O O
continue . . O O
to . . O O
resist . . O O
endoscopic . . O O
screening . . O O
. . . O O

As . . O O
such . . O O
, . . O O
a . . O O
noninvasive . . O O
biomarker . . O O
for . . O O
the . . O O
early . . O O
detection . . O O
of . . O O
CRC . . O O
remains . . O O
a . . O O
priority . . O O
. . . O O

Herein . . O O
, . . O O
we . . O O
( . . O O
i . . O O
) . . O O
review . . O O
the . . O O
currently . . O O
available . . O O
noninvasive . . O O
screening . . O O
markers . . O O
for . . O O
the . . O O
early . . O O
detection . . O O
of . . O O
CRC . . O O
, . . O O
( . . O O
ii . . O O
) . . O O
discuss . . O O
newer . . O O
markers . . O O
that . . O O
have . . O O
undergone . . O O
preliminary . . O O
testing . . O O
, . . O O
and . . O O
( . . O O
iii . . O O
) . . O O
introduce . . O O
and . . O O
explain . . O O
potentially . . O O
promising . . O O
markers . . O O
of . . O O
the . . O O
future . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

The . . O O
published . . O O
literature . . O O
on . . O O
markers . . O O
for . . O O
early . . O O
detection . . O O
of . . O O
CRC . . O O
was . . O O
identified . . O O
using . . O O
a . . O O
MEDLINE . . O O
/ . . O O
PubMed . . O O
search . . O O
with . . O O
secondary . . O O
review . . O O
of . . O O
cited . . O O
publications . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Noninvasive . . O O
testing . . O O
for . . O O
CRC . . O O
is . . O O
most . . O O
advanced . . O O
in . . O O
testing . . O O
for . . O O
stool . . O O
fecal . . O O
occult . . O O
blood . . O O
, . . O O
globin . . O O
, . . O O
or . . O O
DNA . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Study . . O O
of . . O O
abnormal . . O O
mucins . . O O
has . . O O
also . . O O
been . . O O
explored . . O O
. . . O O

Research . . O O
for . . O O
serum . . O O
- . . O O
based . . O O
markers . . O O
is . . O O
just . . O O
beginning . . O O
and . . O O
includes . . O O
serum . . O O
proteomics . . O O
, . . O O
nuclear . . O O
matrix . . O O
proteins . . O O
, . . O O
and . . O O
serum . . O O
DNA . . O O
testing . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Serial . . O O
guaiac . . O O
- . . O O
based . . O O
fecal . . O O
occult . . O O
blood . . O O
testing . . O O
( . . O O
FOBT . . O O
) . . O O
is . . O O
simple . . O O
, . . O O
inexpensive . . O O
, . . O O
and . . O O
proven . . O O
effective . . O O
at . . O O
reducing . . O O
mortality . . O O
from . . O O
CRC . . O O
. . . O O

Immunochemical . . O O
fecal . . O O
occult . . O O
blood . . O O
tests . . O O
facilitate . . O O
compliance . . O O
and . . O O
offer . . O O
improved . . O O
specificity . . O O
, . . O O
but . . O O
at . . O O
increased . . O O
cost . . O O
in . . O O
comparison . . O O
to . . O O
FOBT . . O O
. . . O O

Fecal . . O O
DNA . . O O
testing . . O O
may . . O O
provide . . O O
enhanced . . O O
sensitivity . . O O
for . . O O
detection . . O O
of . . O O
CRC . . O O
in . . O O
comparison . . O O
with . . O O
FOBT . . O O
, . . O O
but . . O O
its . . O O
high . . O O
cost . . O O
limits . . O O
its . . O O
use . . O O
for . . O O
generalized . . O O
screening . . O O
. . . O O

Rectal . . O O
mucin . . O O
testing . . O O
requires . . O O
additional . . O O
evaluation . . O O
to . . O O
determine . . O O
its . . O O
sensitivity . . O O
and . . O O
specificity . . O O
in . . O O
comparison . . O O
with . . O O
guaiac . . O O
- . . O O
based . . O O
FOBT . . O O
. . . O O

Serum . . O O
tests . . O O
, . . O O
such . . O O
as . . O O
proteomics . . O O
, . . O O
nuclear . . O O
matrix . . O O
proteins . . O O
, . . O O
and . . O O
serum . . O O
DNA . . O O
, . . O O
are . . O O
still . . O O
in . . O O
their . . O O
infancy . . O O
, . . O O
but . . O O
remain . . O O
a . . O O
hope . . O O
for . . O O
the . . O O
future . . O O
. . . O O

Loss . . B-Mutation O
of . . I-Mutation O
heterozygosity . . I-Mutation O
of . . O O
APC . . O O
and . . O O
DCC . . O O
tumor . . O O
suppressor . . O O
genes . . O O
in . . O O
human . . O O
sporadic . . O O
colon . . O O
cancer . . O O
. . . O O

We . . O O
examined . . O O
36 . . O O
cases . . O O
of . . O O
human . . O O
sporadic . . O O
colon . . O O
carcinoma . . O O
and . . O O
corresponding . . O O
normal . . O O
tissue . . O O
samples . . O O
to . . O O
evaluate . . O O
loss . . B-Mutation O
of . . I-Mutation O
heterozygosity . . I-Mutation O
at . . O O
the . . O O
APC . . O O
and . . O O
DCC . . O O
tumor . . O O
suppressor . . O O
genes . . O O
loci . . O O
using . . O O
restriction . . O O
fragment . . O O
length . . O O
polymorphism . . O O
polymerase . . O O
chain . . O O
reaction . . O O
and . . O O
variable . . O O
nucleotide . . O O
tandem . . O O
repeat . . O O
analysis . . O O
. . . O O

Observed . . O O
informativity . . O O
was . . O O
83 . . O O
% . . O O
for . . O O
APC . . O O
and . . O O
75 . . O O
% . . O O
for . . O O
DCC . . O O
. . . O O

DNA . . O O
from . . O O
6 . . O O
( . . O O
20 . . O O
% . . O O
) . . O O
of . . O O
30 . . O O
informative . . O O
tumors . . O O
exhibited . . O O
loss . . B-Mutation O
of . . I-Mutation O
heterozygosity . . I-Mutation O
at . . O O
the . . O O
APC . . O O
locus . . O O
. . . O O

Loss . . B-Mutation O
of . . I-Mutation O
heterozygosity . . I-Mutation O
at . . O O
the . . O O
DCC . . O O
locus . . O O
was . . O O
observed . . O O
in . . O O
7 . . O O
( . . O O
26 . . O O
% . . O O
) . . O O
of . . O O
27 . . O O
informative . . O O
tumor . . O O
DNAs . . O O
. . . O O

Our . . O O
results . . O O
support . . O O
the . . O O
view . . O O
that . . O O
malignant . . O O
progression . . O O
is . . O O
a . . O O
consequence . . O O
of . . O O
more . . O O
than . . O O
one . . O O
genetic . . B-Mutation O
change . . I-Mutation O
and . . O O
suggest . . O O
that . . O O
inactivation . . O O
of . . O O
APC . . O O
and . . O O
DCC . . O O
genes . . O O
plays . . O O
a . . O O
role . . O O
in . . O O
a . . O O
multistep . . O O
process . . O O
of . . O O
colon . . O O
tumor . . O O
progression . . O O
. . . O O

Partial . . O O
downregulation . . O O
of . . O O
MAD1 . . O O
causes . . O O
spindle . . O O
checkpoint . . O O
inactivation . . O O
and . . O O
aneuploidy . . O O
, . . O O
but . . O O
does . . O O
not . . O O
confer . . O O
resistance . . O O
towards . . O O
taxol . . O O
. . . O O

The . . O O
mitotic . . O O
spindle . . O O
assembly . . O O
checkpoint . . O O
ensures . . O O
proper . . O O
chromosome . . O O
segregation . . O O
during . . O O
mitosis . . O O
by . . O O
inhibiting . . O O
the . . O O
onset . . O O
of . . O O
anaphase . . O O
until . . O O
all . . O O
kinetochores . . O O
are . . O O
attached . . O O
to . . O O
the . . O O
mitotic . . O O
spindle . . O O
and . . O O
tension . . O O
across . . O O
the . . O O
kinetochores . . O O
is . . O O
generated . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
report . . O O
that . . O O
the . . O O
stable . . O O
partial . . O O
downregulation . . O O
of . . O O
the . . O O
spindle . . O O
checkpoint . . O O
gene . . O O
MAD1 . . O O
, . . O O
which . . O O
is . . O O
observed . . O O
in . . O O
human . . O O
cancer . . O O
, . . O O
leads . . O O
to . . O O
a . . O O
functional . . O O
inactivation . . O O
of . . O O
the . . O O
spindle . . O O
checkpoint . . O O
resulting . . O O
in . . O O
gross . . O O
aneuploidy . . O O
. . . O O

Interestingly . . O O
, . . O O
although . . O O
Mad1 . . O O
is . . O O
thought . . O O
to . . O O
act . . O O
as . . O O
a . . O O
kinetochore . . O O
based . . O O
activator . . O O
of . . O O
Mad2 . . O O
during . . O O
checkpoint . . O O
activation . . O O
, . . O O
we . . O O
show . . O O
that . . O O
normal . . O O
levels . . O O
of . . O O
Mad2 . . O O
, . . O O
but . . O O
not . . O O
of . . O O
Mad1 . . O O
, . . O O
are . . O O
required . . O O
for . . O O
preventing . . O O
premature . . O O
sister . . O O
chromatid . . O O
separation . . O O
and . . O O
for . . O O
maintaining . . O O
the . . O O
timing . . O O
of . . O O
an . . O O
undisturbed . . O O
mitosis . . O O
, . . O O
suggesting . . O O
a . . O O
Mad1 . . O O
independent . . O O
function . . O O
of . . O O
Mad2 . . O O
that . . O O
operates . . O O
independent . . O O
of . . O O
its . . O O
checkpoint . . O O
function . . O O
. . . O O

Most . . O O
significantly . . O O
, . . O O
a . . O O
partial . . O O
repression . . O O
of . . O O
either . . O O
MAD1 . . O O
or . . O O
MAD2 . . O O
confers . . O O
resistance . . O O
to . . O O
nocodazole . . O O
, . . O O
a . . O O
drug . . O O
that . . O O
inhibits . . O O
microtubule . . O O
attachment . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
sensitivity . . O O
to . . O O
clinically . . O O
relevant . . O O
drugs . . O O
like . . O O
taxol . . O O
or . . O O
monastrol . . O O
that . . O O
inhibit . . O O
the . . O O
generation . . O O
of . . O O
tension . . O O
across . . O O
kinetochores . . O O
is . . O O
not . . O O
modulated . . O O
by . . O O
partial . . O O
downregulation . . O O
of . . O O
MAD1 . . O O
, . . O O
suggesting . . O O
a . . O O
functional . . O O
bifurcation . . O O
of . . O O
spindle . . O O
checkpoint . . O O
dependent . . O O
apoptotic . . O O
pathways . . O O
. . . O O

Deciphering . . O O
the . . O O
colon . . O O
cancer . . O O
genes . . O O
- . . O O
- . . O O
report . . O O
of . . O O
the . . O O
InSiGHT . . O O
- . . O O
Human . . O O
Variome . . O O
Project . . O O
Workshop . . O O
, . . O O
UNESCO . . O O
, . . O O
Paris . . O O
2010 . . O O
. . . O O

The . . O O
Human . . O O
Variome . . O O
Project . . O O
( . . O O
HVP . . O O
) . . O O
has . . O O
established . . O O
a . . O O
pilot . . O O
program . . O O
with . . O O
the . . O O
International . . O O
Society . . O O
for . . O O
Gastrointestinal . . O O
Hereditary . . O O
Tumours . . O O
( . . O O
InSiGHT . . O O
) . . O O
to . . O O
compile . . O O
all . . O O
inherited . . O O
variation . . O O
affecting . . O O
colon . . O O
cancer . . O O
susceptibility . . O O
genes . . O O
. . . O O

An . . O O
HVP . . O O
- . . O O
InSiGHT . . O O
Workshop . . O O
was . . O O
held . . O O
on . . O O
May . . O O
10 . . O O
, . . O O
2010 . . O O
, . . O O
prior . . O O
to . . O O
the . . O O
HVP . . O O
Integration . . O O
and . . O O
Implementation . . O O
Meeting . . O O
at . . O O
UNESCO . . O O
in . . O O
Paris . . O O
, . . O O
to . . O O
review . . O O
the . . O O
progress . . O O
of . . O O
this . . O O
pilot . . O O
program . . O O
. . . O O

A . . O O
wide . . O O
range . . O O
of . . O O
topics . . O O
were . . O O
covered . . O O
, . . O O
including . . O O
issues . . O O
relating . . O O
to . . O O
genotype . . O O
- . . O O
phenotype . . O O
data . . O O
submission . . O O
to . . O O
the . . O O
InSiGHT . . O O
Colon . . O O
Cancer . . O O
Gene . . O O
Variant . . O O
Databases . . O O
( . . O O
chromium . . O O
. . . O O
liacs . . O O
. . . O O
nl . . O O
/ . . O O
LOVD2 . . O O
/ . . O O
colon . . O O
_ . . O O
cancer . . O O
/ . . O O
home . . O O
. . . O O
php . . O O
) . . O O
. . . O O

The . . O O
meeting . . O O
also . . O O
canvassed . . O O
the . . O O
recent . . O O
exciting . . O O
developments . . O O
in . . O O
models . . O O
to . . O O
evaluate . . O O
the . . O O
pathogenicity . . O O
of . . O O
unclassified . . O O
variants . . O O
using . . O O
in . . O O
silico . . O O
data . . O O
, . . O O
tumor . . O O
pathology . . O O
information . . O O
, . . O O
and . . O O
functional . . O O
assays . . O O
, . . O O
and . . O O
made . . O O
further . . O O
plans . . O O
for . . O O
the . . O O
future . . O O
progress . . O O
and . . O O
sustainability . . O O
of . . O O
the . . O O
pilot . . O O
program . . O O
. . . O O

[ . . O O
Colorectal . . O O
oncogenesis . . O O
] . . O O
. . . O O

Recent . . O O
progress . . O O
in . . O O
the . . O O
field . . O O
of . . O O
molecular . . O O
biology . . O O
has . . O O
allowed . . O O
us . . O O
to . . O O
identify . . O O
at . . O O
least . . O O
two . . O O
different . . O O
molecular . . O O
mechanisms . . O O
implicated . . O O
in . . O O
colorectal . . O O
carcinogenesis . . O O
( . . O O
CRC . . O O
) . . O O
: . . O O
chromosomal . . B-Mutation O
instability . . I-Mutation O
( . . O O
CIN . . B-Mutation O
) . . O O
and . . O O
genetic . . B-Mutation O
instability . . I-Mutation O
. . . O O

Even . . O O
though . . O O
the . . O O
two . . O O
molecular . . O O
mechanisms . . O O
differ . . O O
, . . O O
their . . O O
signalling . . O O
pathways . . O O
, . . O O
implicated . . O O
in . . O O
malignant . . O O
transformation . . O O
of . . O O
colonic . . O O
epithelial . . O O
cells . . O O
, . . O O
appear . . O O
to . . O O
be . . O O
similar . . O O
. . . O O

The . . O O
most . . O O
frequent . . O O
group . . O O
of . . O O
CRC . . O O
, . . O O
which . . O O
represents . . O O
80 . . O O
% . . O O
of . . O O
sporadic . . O O
CRC . . O O
, . . O O
is . . O O
characterized . . O O
by . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
on . . O O
the . . O O
short . . O O
arm . . O O
of . . O O
chromosome . . O O
17 . . O O
and . . O O
8 . . O O
and . . O O
on . . O O
the . . O O
long . . O O
arm . . O O
of . . O O
chromosome . . O O
5 . . O O
, . . O O
18 . . O O
and . . O O
22 . . O O
. . . O O

These . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
are . . O O
associated . . O O
with . . O O
mutations . . O B-Mutation
in . . O O
TP53 . . O O
, . . O O
APC . . O O
, . . O O
SMAD2 . . O O
and . . O O
SMAD4 . . O O
genes . . O O
. . . O O

All . . O O
of . . O O
these . . O O
alterations . . O O
are . . O O
grouped . . O O
under . . O O
the . . O O
phenotype . . O O
CIN . . B-Mutation O
. . . O O

A . . O O
genetic . . B-Mutation O
instability . . I-Mutation O
termed . . O O
MSI . . B-Mutation B-Mutation
( . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
) . . O O
, . . O O
which . . O O
results . . O O
from . . O O
a . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
deficiency . . O O
, . . O O
appears . . O O
in . . O O
12 . . O O
- . . O O
15 . . O O
% . . O O
of . . O O
CRC . . O O
cases . . O O
. . . O O

The . . O O
presence . . O O
of . . O O
MMR . . O O
deficiency . . O O
leads . . O O
to . . O O
the . . O O
accumulation . . O O
of . . O O
mutations . . B-Mutation B-Mutation
in . . O O
genes . . O O
controlling . . O O
cell . . O O
cycle . . O O
and . . O O
apoptosis . . O O
( . . O O
TGFBRII . . O O
, . . O O
BAX . . O O
or . . O O
CASPASE5 . . O O
) . . O O
. . . O O

More . . O O
recently . . O O
, . . O O
the . . O O
existence . . O O
of . . O O
a . . O O
third . . O O
phenotype . . O O
was . . O O
suggested . . O O
. . . O O

The . . O O
main . . O O
alteration . . O O
associated . . O O
with . . O O
this . . O O
group . . O O
of . . O O
tumors . . O O
is . . O O
the . . O O
hypermethylation . . O O
of . . O O
the . . O O
promoter . . O O
region . . O O
of . . O O
numerous . . O O
genes . . O O
, . . O O
leading . . O O
to . . O O
their . . O O
inactivation . . O O
. . . O O

An . . O O
activating . . O O
mutation . . B-Mutation B-Mutation
of . . O O
BRAF . . O O
is . . O O
frequently . . O O
associated . . O O
with . . O O
this . . O O
phenotype . . O O
. . . O O

As . . O O
described . . O O
above . . O O
, . . O O
CRC . . O O
shows . . O O
genetic . . O O
heterogeneity . . O O
, . . O O
however . . O O
the . . O O
consequences . . O O
in . . O O
terms . . O O
of . . O O
signalling . . O O
pathway . . O O
alterations . . O O
are . . O O
similar . . O O
. . . O O

For . . O O
example . . O O
, . . O O
the . . O O
activation . . O O
of . . O O
Wnt . . O O
signalling . . O O
pathways . . O O
can . . O O
result . . O O
from . . O O
the . . O O
inactivation . . O O
of . . O O
the . . O O
APC . . O O
gene . . O O
in . . O O
the . . O O
CIN . . B-Mutation O
phenotype . . O O
or . . O O
from . . O O
an . . O O
activating . . O O
mutation . . O B-Mutation
in . . O O
the . . O O
 . . O O
- . . O O
catenin . . O O
gene . . O O
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

The . . O O
inactivation . . O O
of . . O O
TGF . . O O
 . . O O
pathways . . O O
is . . O O
also . . O O
present . . O O
in . . O O
both . . O O
tumor . . O O
types . . O O
and . . O O
is . . O O
driven . . O O
by . . O O
SMAD4 . . O O
, . . O O
and . . O O
more . . O O
rarely . . O O
by . . O O
a . . O O
SMAD2 . . O O
inactivating . . O O
mutation . . O B-Mutation
in . . O O
CIN . . B-Mutation O
tumors . . O O
, . . O O
or . . O O
by . . O O
the . . O O
existence . . O O
of . . O O
a . . O O
frame . . B-Mutation O
- . . I-Mutation O
shift . . I-Mutation O
mutation . . I-Mutation B-Mutation
occurring . . O O
in . . O O
a . . O O
polyG . . O O
coding . . O O
track . . O O
of . . O O
the . . O O
TGF . . O O
 . . O O
( . . O O
transforming . . O O
growth . . O O
factor . . O O
) . . O O
receptor . . O O
type . . O O
II . . O O
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

The . . O O
RAS . . O O
- . . O O
MAP . . O O
kinase . . O O
pathway . . O O
is . . O O
activated . . O O
by . . O O
KRAS . . O O
mutations . . B-Mutation B-Mutation
in . . O O
CIN . . B-Mutation O
tumors . . O O
or . . O O
by . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

The . . O O
p53 . . O O
pathway . . O O
is . . O O
inactivated . . O O
by . . O O
TP53 . . O O
inactivation . . O O
in . . O O
CIN . . B-Mutation O
tumors . . O O
or . . O O
by . . O O
BAX . . O O
inactivating . . O O
mutations . . B-Mutation B-Mutation
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

Clinicopathologic . . O O
characteristics . . O O
related . . O O
to . . O O
the . . O O
high . . O O
variability . . O O
of . . O O
coding . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
in . . O O
tumors . . O O
with . . O O
high . . O O
- . . O O
microsatellite . . B-Mutation O
instability . . I-Mutation O
. . . O O

Frameshift . . B-Mutation O
mutation . . I-Mutation B-Mutation
at . . O O
coding . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
are . . O O
common . . O O
in . . O O
tumors . . O O
with . . O O
microsatellite . . B-Mutation O
instability . . I-Mutation O
( . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
) . . O O
, . . O O
but . . O O
the . . O O
incidences . . O O
are . . O O
different . . O O
among . . O O
the . . O O
target . . O O
genes . . O O
. . . O O

We . . O O
analyzed . . O O
the . . O O
mutational . . B-Mutation O
profiles . . O O
of . . O O
12 . . O O
known . . O O
target . . O O
genes . . O O
containing . . O O
polydeoxyadenosine . . O O
repeats . . O O
in . . O O
their . . O O
coding . . O O
sequences . . O O
in . . O O
39 . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
colorectal . . O O
carcinomas . . O O
and . . O O
40 . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
gastric . . O O
carcinomas . . O O
by . . O O
using . . O O
polymerase . . O O
chain . . O O
reaction . . O O
and . . O O
sequencing . . O O
, . . O O
and . . O O
compared . . O O
the . . O O
results . . O O
with . . O O
the . . O O
clinicopathologic . . O O
characteristics . . O O
. . . O O

Frameshift . . B-Mutation O
mutations . . I-Mutation B-Mutation
of . . O O
target . . O O
genes . . O O
in . . O O
the . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
colorectal . . O O
and . . O O
gastric . . O O
carcinomas . . O O
are . . O O
increased . . O O
according . . O O
to . . O O
the . . O O
length . . O O
of . . O O
the . . O O
polydeoxyadenosine . . O O
repeats . . O O
in . . O O
the . . O O
target . . O O
genes . . O O
. . . O O

The . . O O
mean . . O O
mutational . . B-Mutation O
rates . . O O
of . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
colorectal . . O O
carcinomas . . O O
and . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
gastric . . O O
carcinomas . . O O
were . . O O
2 . . O O
. . . O O
03 . . O O
and . . O O
1 . . O O
. . . O O
95 . . O O
in . . O O
the . . O O
4 . . O O
genes . . O O
containing . . O O
( . . O O
A . . O O
) . . O O
10 . . O O
repeats . . O O
, . . O O
1 . . O O
. . . O O
23 . . O O
and . . O O
0 . . O O
. . . O O
73 . . O O
in . . O O
the . . O O
4 . . O O
genes . . O O
with . . O O
( . . O O
A . . O O
) . . O O
9 . . O O
repeats . . O O
and . . O O
0 . . O O
. . . O O
61 . . O O
and . . O O
0 . . O O
. . . O O
48 . . O O
in . . O O
the . . O O
4 . . O O
genes . . O O
containing . . O O
( . . O O
A . . O O
) . . O O
8 . . O O
repeats . . O O
, . . O O
respectively . . O O
( . . O O
p . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
. . . O O

Among . . O O
the . . O O
evaluated . . O O
clinicopathologic . . O O
findings . . O O
, . . O O
intestinal . . O O
type . . O O
gastric . . O O
carcinomas . . O O
had . . O O
more . . O O
frameshift . . B-Mutation O
mutations . . I-Mutation B-Mutation
than . . O O
the . . O O
diffuse . . O O
type . . O O
carcinomas . . O O
( . . O O
3 . . O O
. . . O O
5 . . O O
vs . . O O
. . . O O
1 . . O O
. . . O O
9 . . O O
, . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
01 . . O O
) . . O O
. . . O O

These . . O O
findings . . O O
suggest . . O O
that . . O O
mutational . . B-Mutation O
rates . . O O
of . . O O
the . . O O
target . . O O
genes . . O O
in . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
tumors . . O O
are . . O O
diverse . . O O
, . . O O
and . . O O
higher . . O O
mutational . . B-Mutation O
rates . . O O
are . . O O
related . . O O
to . . O O
the . . O O
length . . O O
of . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
of . . O O
the . . O O
target . . O O
genes . . O O
and . . O O
histologic . . O O
type . . O O
of . . O O
tumors . . O O
. . . O O

MiRNA . . O O
genes . . O O
constitute . . O O
new . . O O
targets . . O O
for . . O O
microsatellite . . O O
instability . . O O
in . . O O
colorectal . . O O
cancer . . O O
. . . O O

Mismatch . . O O
repair . . O O
- . . O O
deficient . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRC . . O O
) . . O O
display . . O O
widespread . . O O
instability . . B-Mutation O
at . . O O
DNA . . O O
microsatellite . . O O
sequences . . O O
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
. . . O O

Although . . O O
MSI . . B-Mutation B-Mutation
has . . O O
been . . O O
reported . . O O
to . . O O
commonly . . O O
occur . . O O
at . . O O
coding . . O O
repeats . . O O
, . . O O
leading . . O O
to . . O O
alterations . . O O
in . . O O
the . . O O
function . . O O
of . . O O
a . . O O
number . . O O
of . . O O
genes . . O O
encoding . . O O
cancer . . O O
- . . O O
related . . O O
proteins . . O O
, . . O O
nothing . . O O
is . . O O
known . . O O
about . . O O
the . . O O
putative . . O O
impact . . O O
of . . O O
this . . O O
process . . O O
on . . O O
non . . O O
- . . O O
coding . . O O
microRNAs . . O O
. . . O O

In . . O O
miRbase . . O O
V15 . . O O
, . . O O
we . . O O
identified . . O O
very . . O O
few . . O O
human . . O O
microRNA . . O O
genes . . O O
with . . O O
mono . . O O
- . . O O
or . . O O
di . . O O
- . . O O
nucleotide . . O O
repeats . . O O
( . . O O
n . . O O
= . . O O
27 . . O O
) . . O O
. . . O O

A . . O O
mutational . . O O
analysis . . O O
of . . O O
these . . O O
sequences . . O O
in . . O O
a . . O O
large . . O O
series . . O O
of . . O O
MSI . . B-Mutation B-Mutation
CRC . . O O
cell . . O O
lines . . O O
and . . O O
primary . . O O
tumors . . O O
underscored . . O O
instability . . B-Mutation O
in . . O O
15 . . O O
of . . O O
the . . O O
24 . . O O
microRNA . . O O
genes . . O O
successfully . . O O
studied . . O O
at . . O O
variable . . O O
frequencies . . O O
ranging . . O O
from . . O O
2 . . O O
. . . O O
5 . . O O
% . . O O
to . . O O
100 . . O O
% . . O O
. . . O O

Following . . O O
a . . O O
maximum . . O O
likelihood . . O O
statistical . . O O
method . . O O
, . . O O
microRNA . . O O
genes . . O O
were . . O O
separated . . O O
into . . O O
two . . O O
groups . . O O
that . . O O
differed . . O O
significantly . . O O
in . . O O
their . . O O
mutation . . O B-Mutation
frequencies . . O O
and . . O O
in . . O O
their . . O O
tendency . . O O
to . . O O
represent . . O O
mutations . . O B-Mutation
that . . O O
may . . O O
or . . O O
may . . O O
not . . O O
be . . O O
under . . O O
selective . . O O
pressures . . O O
during . . O O
MSI . . B-Mutation B-Mutation
tumoral . . O O
progression . . O O
. . . O O

The . . O O
first . . O O
group . . O O
included . . O O
21 . . O O
genes . . O O
that . . O O
displayed . . O O
no . . O O
or . . O O
few . . O O
mutations . . O B-Mutation
in . . O O
CRC . . O O
. . . O O

The . . O O
second . . O O
group . . O O
contained . . O O
three . . O O
genes . . O O
, . . O O
i . . O O
. . . O O
e . . O O
. . . O O
, . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
1273c . . O O
, . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
1303 . . O O
and . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
567 . . O O
, . . O O
with . . O O
frequent . . O O
( . . O O
 . . O O
80 . . O O
% . . O O
) . . O O
and . . O O
sometimes . . O O
bi . . O O
- . . O O
allelic . . O O
mutations . . O B-Mutation
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

For . . O O
the . . O O
only . . O O
one . . O O
expressed . . O O
in . . O O
colonic . . O O
tissues . . O O
, . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
1303 . . O O
, . . O O
no . . O O
direct . . O O
link . . O O
was . . O O
found . . O O
between . . O O
the . . O O
presence . . O O
or . . O O
not . . O O
of . . O O
mono . . O O
- . . O O
or . . O O
bi . . O O
- . . O O
allelic . . O O
alterations . . O O
and . . O O
the . . O O
levels . . O O
of . . O O
mature . . O O
miR . . O O
expression . . O O
in . . O O
MSI . . B-Mutation B-Mutation
cell . . O O
lines . . O O
, . . O O
as . . O O
determined . . O O
by . . O O
sequencing . . O O
and . . O O
quantitative . . O O
PCR . . O O
respectively . . O O
. . . O O

Overall . . O O
, . . O O
our . . O O
results . . O O
provide . . O O
evidence . . O O
that . . O O
DNA . . O O
repeats . . O O
contained . . O O
in . . O O
human . . O O
miRNA . . O O
genes . . O O
are . . O O
relatively . . O O
rare . . O O
and . . O O
preserved . . O O
from . . O O
mutations . . O B-Mutation
due . . O O
to . . O O
MSI . . B-Mutation B-Mutation
in . . O O
MMR . . O O
- . . O O
deficient . . O O
cancer . . O O
cells . . O O
. . . O O

Functional . . O O
studies . . O O
are . . O O
now . . O O
required . . O O
to . . O O
conclude . . O O
whether . . O O
mutated . . O B-Mutation
miRNAs . . O O
, . . O O
and . . O O
especially . . O O
the . . O O
miR . . O O
- . . O O
1303 . . O O
, . . O O
might . . O O
have . . O O
a . . O O
role . . O O
in . . O O
MSI . . B-Mutation B-Mutation
tumorigenesis . . O O
. . . O O
